United Therapeutics CORP Form 4 insider transactions

Linda Maxwell, a Director of UNITED THERAPEUTICS Corp, reported multiple transactions in common stock on July 22, 2026.

Tommy G Thompson, a Director of UNITED THERAPEUTICS Corp, reported multiple transactions in common stock on July 22, 2026.

Kevin Tracey, a Director of UNITED THERAPEUTICS Corp, received 760 shares of common stock on July 22, 2026.

Judy D. Olian, a Director of UNITED THERAPEUTICS Corp, received 760 shares of common stock on July 22, 2026.

Jan Malcolm, a Director of UNITED THERAPEUTICS Corp, reported multiple transactions in common stock on July 22, 2026.

Nilda Mesa, a Director of UNITED THERAPEUTICS Corp, reported multiple transactions in common stock on July 22, 2026.

Louis W Sullivan, a Director of UNITED THERAPEUTICS Corp, received 2,380 shares of common stock on July 22, 2026.

Christopher Causey, a Director of UNITED THERAPEUTICS Corp, received 2,380 shares of common stock on July 22, 2026.

Christopher Patusky, a Director of UNITED THERAPEUTICS Corp, received 2,380 shares of common stock on July 22, 2026.

Richard Giltner, a Director of UNITED THERAPEUTICS Corp, received 760 shares of common stock on July 22, 2026.

Ray Kurzweil, a Director of UNITED THERAPEUTICS Corp, reported multiple transactions in common stock on July 22, 2026.

Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on July 22, 2026.

Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on July 21, 2026.

Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on July 20, 2026.

Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on July 17, 2026.

Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on July 16, 2026.

Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on July 15, 2026.

Paul A Mahon, EVP & GENERAL COUNSEL of UNITED THERAPEUTICS Corp, sold 8,300 shares of common stock on July 16, 2026.

Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on July 14, 2026.

Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on July 13, 2026.

Richard Giltner, a Director of UNITED THERAPEUTICS Corp, reported multiple transactions in common stock on July 9, 2026.

Ray Kurzweil, a Director of UNITED THERAPEUTICS Corp, reported multiple transactions in common stock on July 9, 2026.

Nilda Mesa, a Director of UNITED THERAPEUTICS Corp, reported multiple transactions in common stock on July 9, 2026.

Judy D. Olian, a Director of UNITED THERAPEUTICS Corp, reported multiple transactions in common stock on July 9, 2026.

Christopher Patusky, a Director of UNITED THERAPEUTICS Corp, reported multiple transactions in common stock on July 9, 2026.

Louis W Sullivan, a Director of UNITED THERAPEUTICS Corp, reported multiple transactions in common stock on July 9, 2026.

Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on July 10, 2026.

United Therapeutics Director Jan Malcolm reports transactions involving the acquisition of common stock via restricted stock unit vesting and subsequent sale.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, reported a transaction involving the acquisition of 9,500 common shares on July 9, 2026, under a 10b5-1 trading plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp., reported transactions involving the exercise of stock options and sale of common stock under a pre-arranged 10b5-1 trading plan.